Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.38 |
| ▸ | CTSD | P07339 | 5/20 | 0.36 |
| ▸ | PNMT | P11086 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878568 | 1.00 | BACE1 (0.38) | BACE1BACE2CTSDPNMT | |
| SCHEMBL18195496 | 1.00 | BACE1 (0.38) | BACE1BACE2CTSDPNMT | |
| SCHEMBL17794271 | 0.87 | BACE1 (0.45) | BACE1BACE2CTSD | |
| SCHEMBL22238954 | 0.87 | BACE1 (0.45) | BACE1BACE2CTSD | |
| SCHEMBL12851671 | 0.87 | BACE1 (0.40) | BACE1BACE2CTSD | |
| SCHEMBL12690192 | 0.84 | BACE1 (0.32) | BACE1BACE2 | |
| SCHEMBL18192853 | 0.83 | AKR1B1 (0.33) | BACE1 | |
| SCHEMBL15467741 | 0.82 | BACE1 (0.39) | BACE1BACE2CTSDPNMT | |
| SCHEMBL7704616 | 0.82 | BACE1 (0.39) | BACE1BACE2CTSDPNMT | |
| SCHEMBL16305078 | 0.81 | BACE1 (0.38) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2451793-A1 | BACE INHIBITORS | Eli Lilly and Company (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 28/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.